Gyre Therapeutics IncGYRE
Price$7.00Intrinsic value$8.9628% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $109.8M+3.8% YoYTTM through 30 Jun 2026
Net Income -$28.2M-257.7% YoYTTM through 30 Jun 2026
Free Cash Flow -$6.1MTTM through 30 Jun 2026

Margins

Current
Gross Margin95.4%
EBITDA Margin-17.4%
Operating Margin9.9%
Net Margin-25.7%

Returns

6.9%ROE
6.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio4.70x
Net Debt-$75.9Mnet cash position
Cash & Equivalents$43.3M

Quality Metrics

Altman Z-Score5.00
Piotroski F-Score1 / 9
FCF Margin-5.6%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'18'20'21'22'23'24'25
FY2025: $116.6M
Diluted EPS-$0.21TTM
'11'12'21'22'23'24'25
FY2025: $0.10

Dividend

$3.60Per share, FY20230.00%Yield

Capital Allocation

R&D Spend$17.3M
Capex Intensity1.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.